Late non-malignant complications in aggressive XXXX across four randomized EORTC-trials.

@entity1 @entity137 @entity101 @entity5 @entity3726 @entity1893 @entity978 @entity204
UNASSIGNED: 6528 Background: Late @entity137 has become an important factor influencing the management in survivors of childhood @entity5 and @entity978 . Although, significant proportions of @entity1 with aggressive @entity1893 ( @entity1893 ) become long-term survivors, a systematic analysis on late non-malignant @entity137 in these @entity1 is lacking. An EORTC database of these @entity1 , consistently treated with @entity3726 -like regimens since 1980, offered the possibility to explore late complications in detail. METHODS: Using detailed questionnaires, late complications (>2 years after start therapy) of 757 @entity1 (90%) with a median follow-up of 9.4 (2.1-20.4) years were scored. The cumulative incidences of complications were computed in a competing risk model by Gray (death being the competing event) to avoid bias caused by the high percentage of @entity1893 -related @entity204 . Risk factors were estimated in a Cox proportional-hazards model, but also evaluated with the Gray-test. RESULTS: Late non-neoplastic complications were found in 46% of the @entity1 , see Table. CONCLUSIONS: Half of the @entity1 with aggressive @entity1893 experience late non-neoplastic, mainly cardiovascular or gonadal, complications. Regulation of @entity101 and quitting smoking after treatment may preserve a better quality of life. [Figure: see text] No significant financial relationships to disclose.
